JP2016522196A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016522196A5 JP2016522196A5 JP2016513938A JP2016513938A JP2016522196A5 JP 2016522196 A5 JP2016522196 A5 JP 2016522196A5 JP 2016513938 A JP2016513938 A JP 2016513938A JP 2016513938 A JP2016513938 A JP 2016513938A JP 2016522196 A5 JP2016522196 A5 JP 2016522196A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- subject
- peptide
- improved
- mitochondrial
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 26
- 230000014509 gene expression Effects 0.000 claims description 12
- 230000002438 mitochondrial effect Effects 0.000 claims description 12
- 208000010125 myocardial infarction Diseases 0.000 claims description 12
- 108020005196 Mitochondrial DNA Proteins 0.000 claims description 8
- 239000003087 receptor blocking agent Substances 0.000 claims description 8
- 150000003839 salts Chemical class 0.000 claims description 7
- 239000000556 agonist Substances 0.000 claims description 6
- 210000004027 cell Anatomy 0.000 claims description 6
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 6
- 230000002526 effect on cardiovascular system Effects 0.000 claims description 6
- 229930195729 fatty acid Natural products 0.000 claims description 6
- 239000000194 fatty acid Substances 0.000 claims description 6
- 150000004665 fatty acids Chemical class 0.000 claims description 6
- 230000003647 oxidation Effects 0.000 claims description 6
- 238000007254 oxidation reaction Methods 0.000 claims description 6
- 229940123413 Angiotensin II antagonist Drugs 0.000 claims description 4
- 229940127291 Calcium channel antagonist Drugs 0.000 claims description 4
- 206010061216 Infarction Diseases 0.000 claims description 4
- 229940122202 Thromboxane receptor antagonist Drugs 0.000 claims description 4
- 239000002333 angiotensin II receptor antagonist Substances 0.000 claims description 4
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 claims description 4
- 239000004004 anti-anginal agent Substances 0.000 claims description 4
- 230000001315 anti-hyperlipaemic effect Effects 0.000 claims description 4
- 239000003416 antiarrhythmic agent Substances 0.000 claims description 4
- 229940127218 antiplatelet drug Drugs 0.000 claims description 4
- 102000012740 beta Adrenergic Receptors Human genes 0.000 claims description 4
- 108010079452 beta Adrenergic Receptors Proteins 0.000 claims description 4
- 239000000480 calcium channel blocker Substances 0.000 claims description 4
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 claims description 4
- 229960000830 captopril Drugs 0.000 claims description 4
- 239000002368 cardiac glycoside Substances 0.000 claims description 4
- 229940097217 cardiac glycoside Drugs 0.000 claims description 4
- 239000003246 corticosteroid Substances 0.000 claims description 4
- 229940068811 digitalis preparation Drugs 0.000 claims description 4
- 239000002934 diuretic Substances 0.000 claims description 4
- 230000001882 diuretic effect Effects 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 230000000004 hemodynamic effect Effects 0.000 claims description 4
- 230000007574 infarction Effects 0.000 claims description 4
- 239000003112 inhibitor Substances 0.000 claims description 4
- 230000000297 inotrophic effect Effects 0.000 claims description 4
- 210000004072 lung Anatomy 0.000 claims description 4
- LPMXVESGRSUGHW-HBYQJFLCSA-N ouabain Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@@H]1C[C@@]2(O)CC[C@H]3[C@@]4(O)CC[C@H](C=5COC(=O)C=5)[C@@]4(C)C[C@@H](O)[C@@H]3[C@@]2(CO)[C@H](O)C1 LPMXVESGRSUGHW-HBYQJFLCSA-N 0.000 claims description 4
- 230000001737 promoting effect Effects 0.000 claims description 4
- 239000002516 radical scavenger Substances 0.000 claims description 4
- 238000007634 remodeling Methods 0.000 claims description 4
- 239000000932 sedative agent Substances 0.000 claims description 4
- 230000001624 sedative effect Effects 0.000 claims description 4
- 238000004904 shortening Methods 0.000 claims description 4
- 230000000087 stabilizing effect Effects 0.000 claims description 4
- 229930002534 steroid glycoside Natural products 0.000 claims description 4
- 239000000126 substance Substances 0.000 claims description 4
- 239000002396 thromboxane receptor blocking agent Substances 0.000 claims description 4
- 229940124549 vasodilator Drugs 0.000 claims description 4
- 239000003071 vasodilator agent Substances 0.000 claims description 4
- 230000002861 ventricular Effects 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 3
- 208000007848 Alcoholism Diseases 0.000 claims description 2
- 201000001320 Atherosclerosis Diseases 0.000 claims description 2
- 102000049320 CD36 Human genes 0.000 claims description 2
- 108010045374 CD36 Antigens Proteins 0.000 claims description 2
- 206010013654 Drug abuse Diseases 0.000 claims description 2
- 208000030814 Eating disease Diseases 0.000 claims description 2
- 208000019454 Feeding and Eating disease Diseases 0.000 claims description 2
- 102000058061 Glucose Transporter Type 4 Human genes 0.000 claims description 2
- 101000588298 Homo sapiens Endoplasmic reticulum membrane sensor NFE2L1 Proteins 0.000 claims description 2
- 101000577547 Homo sapiens Nuclear respiratory factor 1 Proteins 0.000 claims description 2
- 101000851700 Homo sapiens Steroid hormone receptor ERR1 Proteins 0.000 claims description 2
- 206010020772 Hypertension Diseases 0.000 claims description 2
- 206010049694 Left Ventricular Dysfunction Diseases 0.000 claims description 2
- 208000009525 Myocarditis Diseases 0.000 claims description 2
- 102100028744 Nuclear respiratory factor 1 Human genes 0.000 claims description 2
- 108010016731 PPAR gamma Proteins 0.000 claims description 2
- 101150014691 PPARA gene Proteins 0.000 claims description 2
- 102000012132 Peroxisome proliferator-activated receptor gamma Human genes 0.000 claims description 2
- 108091006300 SLC2A4 Proteins 0.000 claims description 2
- 102100036832 Steroid hormone receptor ERR1 Human genes 0.000 claims description 2
- 101150080431 Tfam gene Proteins 0.000 claims description 2
- 208000024799 Thyroid disease Diseases 0.000 claims description 2
- 208000036142 Viral infection Diseases 0.000 claims description 2
- 206010000891 acute myocardial infarction Diseases 0.000 claims description 2
- 206010001584 alcohol abuse Diseases 0.000 claims description 2
- 208000025746 alcohol use disease Diseases 0.000 claims description 2
- 231100000457 cardiotoxic Toxicity 0.000 claims description 2
- 230000001451 cardiotoxic effect Effects 0.000 claims description 2
- 230000003081 coactivator Effects 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims description 2
- 210000004351 coronary vessel Anatomy 0.000 claims description 2
- 235000014632 disordered eating Nutrition 0.000 claims description 2
- 230000009395 genetic defect Effects 0.000 claims description 2
- 208000007565 gingivitis Diseases 0.000 claims description 2
- 235000003642 hunger Nutrition 0.000 claims description 2
- 206010020871 hypertrophic cardiomyopathy Diseases 0.000 claims description 2
- 208000031225 myocardial ischemia Diseases 0.000 claims description 2
- 208000008494 pericarditis Diseases 0.000 claims description 2
- 208000011117 substance-related disease Diseases 0.000 claims description 2
- 238000001356 surgical procedure Methods 0.000 claims description 2
- 208000021510 thyroid gland disease Diseases 0.000 claims description 2
- 208000019553 vascular disease Diseases 0.000 claims description 2
- 230000009385 viral infection Effects 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 30
- 239000000150 Sympathomimetic Substances 0.000 claims 2
- 239000002327 cardiovascular agent Substances 0.000 claims 2
- 229940125692 cardiovascular agent Drugs 0.000 claims 2
- 239000003527 fibrinolytic agent Substances 0.000 claims 2
- 230000001975 sympathomimetic effect Effects 0.000 claims 2
- IMCGHZIGRANKHV-AJNGGQMLSA-N tert-butyl (3s,5s)-2-oxo-5-[(2s,4s)-5-oxo-4-propan-2-yloxolan-2-yl]-3-propan-2-ylpyrrolidine-1-carboxylate Chemical compound O1C(=O)[C@H](C(C)C)C[C@H]1[C@H]1N(C(=O)OC(C)(C)C)C(=O)[C@H](C(C)C)C1 IMCGHZIGRANKHV-AJNGGQMLSA-N 0.000 claims 2
- 229960000103 thrombolytic agent Drugs 0.000 claims 2
- 238000011084 recovery Methods 0.000 claims 1
- 230000037351 starvation Effects 0.000 claims 1
- 238000000034 method Methods 0.000 description 27
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 230000002889 sympathetic effect Effects 0.000 description 2
- 230000002537 thrombolytic effect Effects 0.000 description 2
- 229940124345 antianginal agent Drugs 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361823305P | 2013-05-14 | 2013-05-14 | |
| US61/823,305 | 2013-05-14 | ||
| PCT/US2013/066212 WO2014185952A1 (en) | 2013-05-14 | 2013-10-22 | Methods for the prevention or treatment of left ventricle remodeling |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018210291A Division JP2019052157A (ja) | 2013-05-14 | 2018-11-08 | 左室リモデリングの予防または治療のための方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016522196A JP2016522196A (ja) | 2016-07-28 |
| JP2016522196A5 true JP2016522196A5 (enExample) | 2017-02-23 |
Family
ID=51898747
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016513938A Pending JP2016522196A (ja) | 2013-05-14 | 2013-10-22 | 左室リモデリングの予防または治療のための方法 |
| JP2018210291A Pending JP2019052157A (ja) | 2013-05-14 | 2018-11-08 | 左室リモデリングの予防または治療のための方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018210291A Pending JP2019052157A (ja) | 2013-05-14 | 2018-11-08 | 左室リモデリングの予防または治療のための方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (4) | US20160256514A1 (enExample) |
| EP (2) | EP3586864A1 (enExample) |
| JP (2) | JP2016522196A (enExample) |
| CN (2) | CN105579054A (enExample) |
| WO (1) | WO2014185952A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105579054A (zh) * | 2013-05-14 | 2016-05-11 | 康德生物医疗技术公司 | 预防或治疗左心室重塑的方法 |
| US20180318381A1 (en) * | 2015-10-23 | 2018-11-08 | University Of Pittsburgh- Of The Commonwealth System Of Higher Education | Methods of Treatment of Rhabdomyolysis |
| US11034724B2 (en) | 2017-04-05 | 2021-06-15 | Stealth Biotherapeutics Corp. | Crystalline salt forms of Boc-D-Arg-DMT-Lys-(Boc)-Phe-NH2 |
| CN108042525B (zh) * | 2017-12-20 | 2020-09-01 | 岳红 | 一种治疗心肌梗死后心室重塑的药物组合物 |
| US10676506B2 (en) | 2018-01-26 | 2020-06-09 | Stealth Biotherapeutics Corp. | Crystalline bis- and tris-hydrochloride salt of elamipretide |
| GB202000945D0 (en) * | 2020-01-22 | 2020-03-04 | Univ Oslo | Treatment of cardiac remodelling |
| WO2021257673A2 (en) * | 2020-06-17 | 2021-12-23 | Stealth Biotherapeutics Inc. | Methods and compositions for the treatment of muscular dystrophy |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US5858784A (en) | 1991-12-17 | 1999-01-12 | The Regents Of The University Of California | Expression of cloned genes in the lung by aerosol- and liposome-based delivery |
| US5674534A (en) | 1992-06-11 | 1997-10-07 | Alkermes, Inc. | Composition for sustained release of non-aggregated erythropoietin |
| US5716644A (en) | 1992-06-11 | 1998-02-10 | Alkermes, Inc. | Composition for sustained release of non-aggregated erythropoietin |
| US5989463A (en) | 1997-09-24 | 1999-11-23 | Alkermes Controlled Therapeutics, Inc. | Methods for fabricating polymer-based controlled release devices |
| US6245740B1 (en) | 1998-12-23 | 2001-06-12 | Amgen Inc. | Polyol:oil suspensions for the sustained release of proteins |
| CA2947330C (en) * | 2005-09-16 | 2018-06-05 | Cornell Research Foundation, Inc. | Methods for reducing cd36 expression |
| EP2764871A1 (en) * | 2009-10-05 | 2014-08-13 | Cornell University | Methods for the prevention or treatment of heart failure |
| US20130190244A1 (en) * | 2009-12-31 | 2013-07-25 | Stealth Peptides International, Inc. | Methods for performing a coronary artery bypass graft procedure |
| WO2011082324A1 (en) * | 2009-12-31 | 2011-07-07 | Stealth Peptides International, Inc. | Methods for the prevention or treatment of vessel occlusion injury |
| EP2547352A4 (en) * | 2010-03-15 | 2013-10-09 | Stealth Peptides Int Inc | COMBINATION THERAPIES USING CYCLOSPORINE AND AROMATIC CATIONIC PEPTIDES |
| JP6319738B2 (ja) * | 2010-07-09 | 2018-05-09 | ステルス ペプチドズ インターナショナル インコーポレイテッド | 虚血／再灌流障害に続くノーリフローの予防又は処置方法 |
| WO2012115987A2 (en) * | 2011-02-21 | 2012-08-30 | The Trustees Of Columbia University In The City Of New York | Methods for Treating and Preventing Cardiac Dysfunction in Septic Shock |
| WO2013049697A1 (en) * | 2011-09-29 | 2013-04-04 | Mayo Foundation For Medical Education And Research | Aromatic-cationic peptides and methods for using same |
| CN105579054A (zh) * | 2013-05-14 | 2016-05-11 | 康德生物医疗技术公司 | 预防或治疗左心室重塑的方法 |
-
2013
- 2013-10-22 CN CN201380078124.5A patent/CN105579054A/zh active Pending
- 2013-10-22 JP JP2016513938A patent/JP2016522196A/ja active Pending
- 2013-10-22 CN CN201811549998.5A patent/CN110051843A/zh active Pending
- 2013-10-22 EP EP19172063.0A patent/EP3586864A1/en active Pending
- 2013-10-22 EP EP13884895.7A patent/EP2996707B1/en active Active
- 2013-10-22 WO PCT/US2013/066212 patent/WO2014185952A1/en not_active Ceased
- 2013-10-22 US US14/891,205 patent/US20160256514A1/en not_active Abandoned
-
2018
- 2018-11-08 JP JP2018210291A patent/JP2019052157A/ja active Pending
- 2018-11-15 US US16/192,728 patent/US20190358286A1/en not_active Abandoned
-
2022
- 2022-02-25 US US17/680,842 patent/US20220296671A1/en not_active Abandoned
-
2024
- 2024-11-21 US US18/954,860 patent/US20250319152A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022046811A5 (enExample) | ||
| JP6526306B2 (ja) | バルドキソロンメチルまたはその類似体を使用して内皮機能障害を処置および予防する方法 | |
| JP2013506696A5 (enExample) | ||
| CN103429236B (zh) | 治疗高尿酸血症和与高尿酸血症相关的代谢性病症的方法和组合物 | |
| JP2016503397A5 (enExample) | ||
| Ergul | Endothelin‐1 and endothelin receptor antagonists as potential cardiovascular therapeutic agents | |
| CN1655819A (zh) | 包含肾素抑制剂、钙通道阻断剂和利尿药的药物组合物 | |
| JP2016511259A5 (enExample) | ||
| CN105358150A (zh) | 用于心脏病的bet抑制疗法 | |
| CN105338975B (zh) | 用于治疗癌症的氧烯洛尔组合物 | |
| WO2010015939A1 (en) | Use of dronedarone for the preparation of a medicament for the prevention of stroke or transient ischemic attack | |
| AU2017328999B2 (en) | Combination of FXR agonists | |
| Passalia et al. | Cardiovascular adverse events complicating the administration of rituximab: report of two cases | |
| CN114450067A (zh) | 人受试者的心力衰竭的治疗 | |
| JPWO2005105793A1 (ja) | 筋弛緩促進剤及び筋弛緩不全等の筋組織に係る疾病の治療薬 | |
| PT1587584E (pt) | Combinação farmacêutica para a profilaxia ou terapia de doenças cardiovasculares, cardiopulmonares, pulmonares ou renais | |
| Pozzi et al. | Potential therapeutic targets in cirrhotic cardiomyopathy | |
| Lee et al. | Additive effects of combined blockade of AT1 receptor and HMG-CoA reductase on left ventricular remodeling in infarcted rats | |
| JP2025508932A5 (enExample) | ||
| JP2008528704A5 (enExample) | ||
| JP4525964B2 (ja) | 肺高血圧症予防治療剤 | |
| JPWO2015152393A1 (ja) | 悪性腫瘍転移抑制用医薬 | |
| Asif | A brief survey of clinically used various cardiovascular agents | |
| US20200179388A1 (en) | Vasodilators for treatment of heart failure | |
| JP4783887B2 (ja) | 心筋組織の障害を抑制するための医薬組成物 |